Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Thomas E Witzig, M.D.
Mayo Clinic
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Health Systems-Mankato
Mankato, Minnesota, United States
Stephan D. Thome, M.D.Not, yet, recruiting - Mayo Clinic in Rochester
Rochester, Minnesota, United States
Thomas E. Witzig, M.D.Recruiting - Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin, United States
Eyad S. Al-Hattab, M.D.Not, yet, recruiting - Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, United States
Active, not recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Mar 2018
- Primary completion
- 22 Feb 2031
- Completion
- 2 Nov 2033
- Last update posted
- 16 Apr 2026
- Registered enrollment
- 80
- Registry id
- NCT03418038
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.